MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Adel A. F. Mahmoud, M.D., Ph.D joins Sanaria Board of Directors
Sanaria is pleased to announce that Adel A. F. Mahmoud, M.D., Ph.D, of the Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University and former President of Merck Vaccines, was elected to Sanaria's Board of Directors.
Whole parasite malaria vaccine to be manufactured for clinical trials
Sanaria Inc. and the PATH Malaria Vaccine Initiative has officially opened a one-of-a- kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.
Researchers aim to use mosquitoes to bite back at malaria
A US scientist is leading an international team of researchers using an army of blood- sucking mosquitoes to produce a potentially potent vaccine against malaria.
Malaria vaccine plant takes a gamble
In a nondescript office park tucked between a hospital and a strip mall thrive hundreds of thousands of the most infectious malaria-carrying mosquitoes ever born. They will be dissected for the motherlode that they carry -- baby malaria parasites, fodder for a new malaria vaccine.
Sanaria, PATH Malaria Vaccine Initiative Open Manufacturing Facility For Producing World’s First “Whole-Parasite” Malaria Vaccine
Sanaria Inc. and the PATH Malaria Vaccine Initiative today officially opened a one-of-a-kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.